Who
Matthew Shields
EVP, Global Operations
Company insider
Files Form 4 as: EVP, Global Operations, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $2.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Jun 2024
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $322K9,989 at $32.19 | filing |
| 18 Jun 2026filed 22 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $322K9,989 at $32.19 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —16,195 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $532K16,195 at $32.87 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,195 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,195 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —16,195 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $532K16,195 at $32.87 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —17,295 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $548K17,295 at $31.67 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —17,295 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —17,295 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —17,295 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $548K17,295 at $31.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —33,424 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —33,424 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,195 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —16,195 | filing |
| 3 Jun 2025filed 5 Jun 2025 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $106K6,206 at $17.02 | filing |
| 5 Mar 2025filed 7 Mar 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —69,182 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Matthew Shields; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.